Inovio stock: Piper Sandler keeps USD 4.00 target for Inovio stock

Published on 10/22/2026 at 19:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cash stood at USD 31.53 million on June 30, 2026. Inovio stock costs EUR 0.74 on October 22, 2026 at a USD 57.4 million market value.

Analyst and balance sheet

On October 21, 2026, Piper Sandler analyst Edward Tenthoff set a USD 4.00 target and reiterated Buy for Inovio.
In the second quarter of 2026, the GAAP net loss narrowed to USD 6.01 million from USD 23.52 million.
Inovio stock costs EUR 0.74 at Lang & Schwarz on October 22, 2026 at 7:04 p.m. CEST.

INO, US45773H4092, Illustration mit AI erstellt.

Inovio Pharmaceuticals (ISIN US45773H4092) received a fresh analyst signal on October 21, 2026, when Piper Sandler analyst Edward Tenthoff reiterated a Buy rating and set a USD 4.00 price target, as Markets Insider reported. Inovio was trading at EUR 0.74 at Lang & Schwarz on October 22, 2026 at 7:04 p.m. CEST.

Target follows narrower loss

The analyst action came after Inovio reported a GAAP net loss of USD 6.01 million for the second quarter of 2026, compared with a USD 23.52 million loss in the second quarter of 2025. The comparison was included in the Markets Insider report dated October 21, 2026, which also identified the latest Piper Sandler view.

Cash and regulatory date matter

Inovio held USD 36.70 million in cash, cash equivalents and short-term investments at the end of the second quarter, while management expected those resources to fund operations into late first quarter 2027, according to AInvest on October 21, 2026. The same report said the FDA decision on INO-3107 is scheduled for October 30, 2026, with accelerated-approval eligibility still a central issue.

Market value stays compressed

The USD 57.4 million market capitalization and USD 0.56 to USD 2.72 52-week range were dated October 22, 2026. The EUR quote therefore remains a small-cap biotechnology market signal, while the company continues to depend on clinical and regulatory progress rather than established product revenue.

What comes next for investors

Inovio's Nasdaq listing carries the ticker INO. The upcoming October 30, 2026 FDA decision is the next dated event, while the third-quarter earnings report is expected around November 10, 2026, according to AInvest.

Stock price and market value

Inovio was trading at EUR 0.74 at Lang & Schwarz on October 22, 2026 at 7:04 p.m. CEST. Its market capitalization was USD 57.4 million on October 22, 2026, and its Nasdaq 52-week range was USD 0.56 to USD 2.72. The further course of trading is shown by the continuously updated real-time quote of Inovio Pharmaceuticals stock.